Medical devices, healthcare technology and the business of care
PMA approval · P260004

Signatera CDx

Natera, Inc. · Decision date May 15, 2026

FDA DECISIONP260004

What did the FDA approve?

FDA records P260004 as an original PMA application. The recorded decision is approval, dated May 15, 2026.

FDA approval order statement

SignateraTM CDx is a personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS)based assay that detects circulating tumor DNA (ctDNA) molecular residual disease (MRD) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs), using bespoke assays designed to track somatic variants identified from sequencing of a patients formalin-fixed, paraffin-embedded (FFPE) tumor specimen.SignateraTM CDx is intended to identify patients with ctDNA MRD positive status who may benefit from treatment listed in Table 1, in accordance with the approved therapeutic product labeling.Table 1: SignateraTM CDx Indicated Use and Associated TherapyBiomarker Indication TherapyctDNA MRD Muscle Invasive Bladder Cancer (MIBC) TECENTRIQ (atezolizumab), TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs)
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
May 15, 2026

FDA source record

Regulatory record facts

Identifier
P260004
Regulatory pathway
Premarket approval application
Applicant
Natera, Inc.
Product code
PQP
Decision code
APPR
Decision date
May 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Applicant
Natera, Inc.
Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P260004 received

    Application receipt date recorded by FDA.

  2. P260004 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P260004. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Natera, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
13011a Mccallen Pass, Austin, TX, 78753

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records